What is Bharat Biotech considering regarding its future finances?

Bharat Biotech is considering an initial public offering (IPO) that could raise more than $500 million.

How many vaccines has Bharat Biotech delivered worldwide?

Since its founding in 1996, Bharat Biotech has delivered over 9 billion vaccines globally.

How is India's IPO market performing in early 2026?

India's market for first-time share sales has had a slow start to 2026 after two consecutive years of record fundraising.

Home / Business and Economy / Bharat Biotech Eyes $500M IPO Amid Market Slowdown

Bharat Biotech Eyes $500M IPO Amid Market Slowdown

27 Feb

•

Summary

Bharat Biotech is exploring an IPO to raise over $500 million.
The vaccine developer has supplied over 9 billion vaccines globally.
India's IPO market faces a slow start in 2026 after record years.

Bharat Biotech Eyes $500M IPO Amid Market Slowdown

Bharat Biotech International Ltd., a prominent Indian vaccine developer, is reportedly considering an initial public offering (IPO) that could potentially raise over $500 million. Discussions regarding the specifics of this potential deal, including its final size and timeline, are ongoing.

Established in 1996, Bharat Biotech has a substantial global footprint, having delivered more than 9 billion vaccines. Their product portfolio includes critical vaccines against COVID-19 and hepatitis B, alongside treatments for burns and diarrhea.

The Indian market for initial public offerings has seen a subdued beginning to 2026, following two consecutive years of record-breaking fundraising activities. Factors such as decelerating earnings growth, global trade uncertainties, and inconsistent foreign investment inflows have impacted stock performance.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.